A series of 4'-C-(hydroxymethyl) analogs of pyrimidine and purine nucleosides have been prepared utilizing standard methodologies, and the α and β anomers were separated. These analogs are part of our continuing efforts to identify new anticancer drugs as well as to explore the substrate specificities of these analogs with the initial activating enzymes in the metabolic pathway leading to nucleoside triphosphates. Although not cytotoxic to CCRF-CEM cells (an acute lymphoblastic leukemia of T-cell origin), many of these compounds were utilized as substrates for the various human nucleoside kinases, including deoxycytidine kinase, thymidine kinase 1, and thymidine kinase 2. Because the 4'-C-(hydroxymethyl) analog of arabinofuranosyl cytosine was identified as a good substrate with deoxycytidine kinase, its metabolism in CEM cells was evaluated. These results indicated that nucleosides with this modification could be activated in human cells without cytotoxicity, which suggested that they should be examined for antiviral activity.
一系列4'-
C-(
羟甲基)
嘧啶和
嘌呤核苷类似物已经利用标准方法制备,α和β异构体已被分离。这些类似物是我们持续努力寻找新的抗癌药物以及探索这些类似物与引导核苷
三磷酸的代谢途径中的初始激活酶的底物特异性的一部分。尽管对CCRF-C
EM细胞(一种T细胞来源的急性淋巴细胞白血病)没有细胞毒性,但许多这些化合物被用作各种人类
核苷酸激酶的底物,包括
脱氧胞苷激酶、
胸苷激酶1和
胸苷激酶2。由于4'-
C-(
羟甲基)阿拉伯
核糖胞嘧啶类似物被鉴定为与
脱氧胞苷激酶具有良好的底物特性,因此对其在C
EM细胞中的代谢进行了评估。这些结果表明,带有这种修饰的核苷类似物可以在人类细胞中被激活而不具有细胞毒性,这表明它们应该被检查其抗病毒活性。